Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Company Deals

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Fineline Cube Feb 12, 2026
Company Deals

Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs

Fineline Cube Feb 12, 2026
Company Deals

Jingxin Pharmaceutical Files Hong Kong IPO for Dual Listing Strategy

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

Fineline Cube Feb 12, 2026
Company Drug

Henlius Biotech Initiates Phase Ib/II Study for HLX43 ADC Combinations in Colorectal Cancer

Fineline Cube Feb 12, 2026
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025

Xinyuan Zhenghe (Hangzhou) Private Equity Fund Management Co., Ltd., Sirnaomics, and the Fuyang Economic and...

Hospital

Hainan Opens First Wholly Foreign-Owned Hospital Ahead of Free Trade Port Launch

Fineline Cube Dec 18, 2025

Boao Fullerton Hospital, the first wholly foreign‑owned hospital in Hainan, held its unveiling ceremony today...

Company Drug

Hutchmed’s HMPL-A251 ATTC Dosed in Global Phase 1 for HER2 Tumors

Fineline Cube Dec 18, 2025

Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the initiation of a...

Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025

HBM Holdings Limited (HKG: 2142) announced it has entered into a long-term global strategic collaboration...

Company Drug

Antengene Xpovio sNDA Malaysia Approval Expands DLBCL Indication

Fineline Cube Dec 18, 2025

Antengene Corporation Limited (HKG: 6996) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved...

Company Drug

Everest lerodalcibep PCSK9 FDA Approval Targets China Launch

Fineline Cube Dec 18, 2025

Everest Medicines Limited (HKG: 1952) announced that the U.S. FDA has approved the Biologics License...

Company Medical Device

Cryofocus GERD System Secures NMPA Approval in China

Fineline Cube Dec 18, 2025

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced that its Anti-Gastroesophageal Reflux System has been...

Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025

Sanofi (NASDAQ: SNY) announced a license agreement with South Korean biotech Adel to gain exclusive...

Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Fineline Cube Dec 17, 2025

Byterna Therapeutics completed its angel plus round financing, exclusively invested by Efung Capital. Proceeds will...

Company Drug

GSK’s Exdensur Wins FDA Approval as First Twice‑Yearly Asthma Biologic

Fineline Cube Dec 17, 2025

GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) approved...

Hospital

Beijing Friendship Hospital Launches Cell and Gene Therapy Center for Liver Diseases

Fineline Cube Dec 17, 2025

The Cell and Gene Therapy Innovation and Transformation Center was officially established at Beijing Friendship...

Company Deals

Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal

Fineline Cube Dec 17, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving...

Company Deals

Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones

Fineline Cube Dec 17, 2025

Jiangsu Hansoh Pharmaceutical Co. Ltd. (HKG: 3692) entered into an exclusive license, collaboration, and distribution...

Company Deals

Fangzhou and Huilun Partner on AI-Driven Chronic Disease Management Platform

Fineline Cube Dec 17, 2025

Guangzhou-based smart healthcare service platform Fangzhou Inc. (HKG: 6086) and Shanghai Huilun Pharmaceutical Co., Ltd....

Company Drug

Adagene’s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo

Fineline Cube Dec 17, 2025

Adagene Inc. (NASDAQ: ADAG) announced that the U.S. Food and Drug Administration (FDA) granted Fast...

Company Drug

Aficamten Wins China Approval as HCM Drug in Global First for Sanofi

Fineline Cube Dec 17, 2025

Sanofi (NASDAQ: SNY) announced that aficamten, a second‑generation cardiac myosin inhibitor, received marketing approval from...

Company Drug

Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline

Fineline Cube Dec 17, 2025

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Fineline Cube Dec 16, 2025

InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self‑developed novel BTK inhibitor orelabrutinib...

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025

Saizeng Medical Technology Co. Ltd, a subsidiary of Changchun High‑Tech Industry (Group) Co., Ltd. (SHE:...

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Fineline Cube Dec 16, 2025

Zhicheng Medical Technology (Jiaxing) Co., Ltd. announced that its self‑developed ReachTact Transcatheter Aortic Valve Replacement...

Posts pagination

1 … 25 26 27 … 624

Recent updates

  • Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals
  • Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion
  • Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials
  • MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer
  • Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Company Deals

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Company Drug

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.